In today's post, we share an article published by 36Kr.com (NASDAQ: KRKR), a leading Chinese platform for new economy, technology, and business insights
This isn't a medical distinction
Take the pregnancy metaphor: If someone is not pregnant, the question can bring unwanted attention to their body shape or size
GIP Receptor Activation The additional advantage
STEP-1 Trial (Semaglutide 2.4 mg, N=1,961) The STEP-1 trial published in the New England Journal of Medicine reported that among participants receiving semaglutide 2.4 mg subcutaneously once weekly, nausea occurred in 44.2%, diarrhea in 29.7%, vomiting in 24.5%, and constipation in 24.1%, compared to 16.0%, 15.9%, 6.8%, and 11.1% with placebo, respectively [3]
Most of Saxendas side effects are mild, dose-dependent, and typically gastrointestinal-related